GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OKYO Pharma Ltd (NAS:OKYO) » Definitions » Price-to-Free-Cash-Flow

OKYO Pharma (OKYO Pharma) Price-to-Free-Cash-Flow : N/A (As of May. 29, 2024)


View and export this data going back to 2022. Start your Free Trial

What is OKYO Pharma Price-to-Free-Cash-Flow?

As of today (2024-05-29), OKYO Pharma's share price is $1.3105. OKYO Pharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.09. Hence, OKYO Pharma's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for OKYO Pharma's Price-to-Free-Cash-Flow or its related term are showing as below:

OKYO's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.36
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

OKYO Pharma's Free Cash Flow per Share for the six months ended in Mar. 2023 was $-0.09. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.09.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -457.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -124.70% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was -10.40% per year.

During the past 13 years, OKYO Pharma's highest 3-Year average Free Cash Flow per Share Growth Rate was 60.00% per year. The lowest was -457.20% per year. And the median was -10.10% per year.


OKYO Pharma Price-to-Free-Cash-Flow Historical Data

The historical data trend for OKYO Pharma's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OKYO Pharma Price-to-Free-Cash-Flow Chart

OKYO Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OKYO Pharma Semi-Annual Data
Sep13 Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OKYO Pharma's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, OKYO Pharma's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OKYO Pharma's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OKYO Pharma's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where OKYO Pharma's Price-to-Free-Cash-Flow falls into.



OKYO Pharma Price-to-Free-Cash-Flow Calculation

OKYO Pharma's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1.3105/-0.089
=N/A

OKYO Pharma's Share Price of today is $1.3105.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. OKYO Pharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.09.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

OKYO Pharma  (NAS:OKYO) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


OKYO Pharma Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of OKYO Pharma's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


OKYO Pharma (OKYO Pharma) Business Description

Traded in Other Exchanges
Address
14/15 Conduit St, Floor 4, London, GBR, W1S 2XJ
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
Executives
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob director, officer: Chief Executive Officer
Gabriele M Cerrone director, 10 percent owner, officer: Executive Chairman 265 EAST 66TH STREET, SUITE 16G, NEW YORK NY 10021
Bernard Denoyer director C/O CALLISTO PHARMACEUTICALS, INC., 420 LEXINGTON AVENUE, SUITE 1609, NEW YORK NY 10170
Willy Jules Simon director PLAYLOGIC INTERNATIONAL NV, CONCERTGEBOUWPLEIN 13, AMSTERDAM P7 1071 LL
Keeren Shah officer: Chief Financial Officer 55 PARK LANE, LONDON X0 W1K 1NA